The biotechnology company’s messenger RNA flu vaccine candidate showed positive results in a late-stage trial.

Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...

FluMist is the first vaccine to prevent influenza, more commonly known as the flu, that does not need to be administered by a ...

Influenza hemagglutinin subunit vaccines are more effective and offer better cross protection against various influenza virus ...

The Cambridge biotech believes packaging the two immunizations together will lead to higher uptake of COVID vaccines.

In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the ...

Moderna Inc. said Monday its experimental flu shot showed positive results in a late-stage trial.   In a Phase 3 study, the ...

RNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed ...

The virus has not yet evolved to spread efficiently between people. Excellent vaccine technology exists, but the government ...

The Department of Agriculture has issued its first-ever permit to vaccinate poultry against highly pathogenic avian influenza ...

The preservative thimerosal started Robert F. Kennedy Jr. down the path of questioning vaccine safety. A panel of experts he ...

The latest phase 3 win is a boost for Moderna’s attempts to create a flu/COVID combination vaccine. The company withdrew a filing for FDA approval for its combo candidate last month while it waited ...